木瓜直播

U.S. News & World Report released its .

Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) over ADT alone in metastatic hormone-sensitive prostate cancer in the ARANOTE trial, meeting the phase III study's primary endpoint, Bayer announced.

Meanwhile, results of the phase III TiNivo-2 trial in advanced metastatic renal cell carcinoma showed that post-immunotherapy treatment with nivolumab (Opdivo) and a low dose of tivozanib (Fotivda) versus a standard dose of tivozanib alone, AVEO Oncology announced.

Hydroxyurea had for girls and young women living with sickle cell disease, a study showed, suggesting that fertility preservation measures prior to treatment may be unnecessary. (Blood Advances)

Use of cyclophosphamide-based graft-versus-host disease prophylaxis after an allogeneic hematopoietic cell transplant between matched and mismatched unrelated donors. (Journal of Clinical Oncology)

A population-based study suggests the affects the health outcomes of blood cancer patients who undergo hematopoietic cell transplantation. (PNAS)

Women are more likely to die from breast and cervical cancers in a where preventive care lags behind the rest of the country, according to a Commonwealth Fund analysis.

New federal guidelines for people with HIV as part of an anal cancer screening program to help detect and treat precancers. (National Institutes of Health)

Current screening protocols associated with Lynch syndrome and hereditary breast and ovarian cancer syndrome. (JCO Precision Oncology)

Neha Vapiwala, MD, of the University of Pennsylvania in Philadelphia, was voted .

The FDA is advising for the investigational immunotherapy combination of botensilimab and balstilimab for relapsed/refractory microsatellite stable colorectal cancer, said drugmaker Agenus.

A 29-year-old Ohio man has filed a lawsuit accusing two dozen companies of contaminating his water supply with fluorochemicals and . (Newsweek)

Comment